메뉴 건너뛰기




Volumn 18, Issue 1, 2016, Pages

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: A biomarker study of MOBILITY

Author keywords

Biomarker; RANKL OPG; Rheumatoid arthritis; Sarilumab

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; SARILUMAB; STROMELYSIN; ANTIRHEUMATIC AGENT; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; MONOCLONAL ANTIBODY;

EID: 84991666306     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1132-9     Document Type: Article
Times cited : (40)

References (40)
  • 4
    • 84993748500 scopus 로고    scopus 로고
    • The role of interleukin 6 in the pathophysiology of rheumatoid arthritis
    • Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2010;2:247-56.
    • (2010) Ther Adv Musculoskelet Dis , vol.2 , pp. 247-256
    • Srirangan, S.1    Choy, E.H.2
  • 5
    • 0023942493 scopus 로고
    • Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
    • Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31:784-8.
    • (1988) Arthritis Rheum , vol.31 , pp. 784-788
    • Houssiau, F.A.1    Devogelaer, J.P.2    Van Damme, J.3    de Deuxchaisnes, C.N.4    Van Snick, J.5
  • 7
    • 13344250490 scopus 로고    scopus 로고
    • Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
    • Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11:88-95.
    • (1996) J Bone Miner Res , vol.11 , pp. 88-95
    • Kotake, S.1    Sato, K.2    Kim, K.J.3    Takahashi, N.4    Udagawa, N.5    Nakamura, I.6
  • 8
    • 0033120581 scopus 로고    scopus 로고
    • Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products
    • Garnero P, Jouvenne P, Buchs N, Delmas PD, Miossec P. Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. Bone. 1999;24:381-5.
    • (1999) Bone , vol.24 , pp. 381-385
    • Garnero, P.1    Jouvenne, P.2    Buchs, N.3    Delmas, P.D.4    Miossec, P.5
  • 9
    • 54449101331 scopus 로고    scopus 로고
    • IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-a and IL-17
    • Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-a and IL-17. Rheumatology (Oxford). 2008;47:1635-40.
    • (2008) Rheumatology (Oxford) , vol.47 , pp. 1635-1640
    • Hashizume, M.1    Hayakawa, N.2    Mihara, M.3
  • 11
    • 0028786577 scopus 로고
    • Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors
    • Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Findlay DM, et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med. 1995;182:1461-8.
    • (1995) J Exp Med , vol.182 , pp. 1461-1468
    • Udagawa, N.1    Takahashi, N.2    Katagiri, T.3    Tamura, T.4    Wada, S.5    Findlay, D.M.6
  • 12
    • 0037265995 scopus 로고    scopus 로고
    • Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism
    • Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1-7.
    • (2003) Bone , vol.32 , pp. 1-7
    • Kudo, O.1    Sabokbar, A.2    Pocock, A.3    Itonaga, I.4    Fujikawa, Y.5    Athanasou, N.A.6
  • 13
    • 0035089788 scopus 로고    scopus 로고
    • The role of osteoprotegerin and receptor activator of nuclear factor kB ligand in the pathogenesis and treatment of rheumatoid arthritis
    • Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum. 2001;44:253-9.
    • (2001) Arthritis Rheum , vol.44 , pp. 253-259
    • Hofbauer, L.C.1    Heufelder, A.E.2
  • 14
    • 69449090213 scopus 로고    scopus 로고
    • Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo
    • Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum. 2009;60:2747-56.
    • (2009) Arthritis Rheum , vol.60 , pp. 2747-2756
    • Axmann, R.1    Böhm, C.2    Krönke, G.3    Zwerina, J.4    Smolen, J.5    Schett, G.6
  • 15
    • 45849120200 scopus 로고    scopus 로고
    • Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model
    • Kato A, Matsuo S, Takai H, Uchiyama Y, Mihara M, Suzuki M. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp Mol Pathol. 2008;84:262-70.
    • (2008) Exp Mol Pathol , vol.84 , pp. 262-270
    • Kato, A.1    Matsuo, S.2    Takai, H.3    Uchiyama, Y.4    Mihara, M.5    Suzuki, M.6
  • 16
    • 33745030280 scopus 로고    scopus 로고
    • The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction
    • Geusens PP, Landewé RB, Garnero P, Chen D, Dunstan CR, Lems WF, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum. 2006;54:1772-7.
    • (2006) Arthritis Rheum , vol.54 , pp. 1772-1777
    • Geusens, P.P.1    Landewé, R.B.2    Garnero, P.3    Chen, D.4    Dunstan, C.R.5    Lems, W.F.6
  • 17
    • 64849102229 scopus 로고    scopus 로고
    • Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression
    • Syversen SW, Goll GL, van der Heijde D, Landewé R, Gaarder PI, Odegård S, et al. Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol. 2009;36:266-72.
    • (2009) J Rheumatol , vol.36 , pp. 266-272
    • Syversen, S.W.1    Goll, G.L.2    van der Heijde, D.3    Landewé, R.4    Gaarder, P.I.5    Odegård, S.6
  • 18
    • 84894903557 scopus 로고    scopus 로고
    • Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study
    • Bay-Jensen AC, Platt A, Byrjalsen I, Vergnoud P, Christiansen C, Karsdal MA. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin Arthritis Rheum. 2014;43:470-8.
    • (2014) Semin Arthritis Rheum , vol.43 , pp. 470-478
    • Bay-Jensen, A.C.1    Platt, A.2    Byrjalsen, I.3    Vergnoud, P.4    Christiansen, C.5    Karsdal, M.A.6
  • 20
    • 0142093504 scopus 로고    scopus 로고
    • Biochemical markers of joint tissue turnover in early rheumatoid arthritis
    • Garnero P, Geusens P, Landewé R. Biochemical markers of joint tissue turnover in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21 Suppl 31:S54-8.
    • (2003) Clin Exp Rheumatol , vol.21 , pp. S54-S58
    • Garnero, P.1    Geusens, P.2    Landewé, R.3
  • 21
    • 84872171342 scopus 로고    scopus 로고
    • Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study
    • Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int. 2012;32:3565-72.
    • (2012) Rheumatol Int , vol.32 , pp. 3565-3572
    • Bay-Jensen, A.C.1    Leeming, D.J.2    Kleyer, A.3    Veidal, S.S.4    Schett, G.5    Karsdal, M.A.6
  • 23
    • 84864778747 scopus 로고    scopus 로고
    • Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis
    • Skjøt-Arkil H, Schett G, Zhang C, Larsen DV, Wang Y, Zheng Q, et al. Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2012;30:371-9.
    • (2012) Clin Exp Rheumatol , vol.30 , pp. 371-379
    • Skjøt-Arkil, H.1    Schett, G.2    Zhang, C.3    Larsen, D.V.4    Wang, Y.5    Zheng, Q.6
  • 24
    • 84929881847 scopus 로고    scopus 로고
    • Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study
    • Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67:1424-37.
    • (2015) Arthritis Rheumatol , vol.67 , pp. 1424-1437
    • Genovese, M.C.1    Fleischmann, R.2    Kivitz, A.J.3    Rell-Bakalarska, M.4    Martincova, R.5    Fiore, S.6
  • 25
    • 84902316860 scopus 로고    scopus 로고
    • Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) alpha
    • Rafique A, Martin J, Blome M, Huang T, Ouyang A, Papadopoulos N. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) alpha. Ann Rheum Dis. 2013;72 Suppl 3:A797.
    • (2013) Ann Rheum Dis , vol.72 , pp. A797
    • Rafique, A.1    Martin, J.2    Blome, M.3    Huang, T.4    Ouyang, A.5    Papadopoulos, N.6
  • 26
    • 84905179575 scopus 로고    scopus 로고
    • Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RAMOBILITY Part A trial
    • Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ra in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RAMOBILITY Part A trial. Ann Rheum Dis. 2014;73:1626-34.
    • (2014) Ann Rheum Dis , vol.73 , pp. 1626-1634
    • Huizinga, T.W.1    Fleischmann, R.M.2    Jasson, M.3    Radin, A.R.4    van Adelsberg, J.5    Fiore, S.6
  • 28
    • 0023024460 scopus 로고
    • A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization
    • Okada Y, Nagase H, Harris Jr ED. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem. 1986;261:14245-55.
    • (1986) J Biol Chem , vol.261 , pp. 14245-14255
    • Okada, Y.1    Nagase, H.2    Harris, E.D.3
  • 29
    • 74849102659 scopus 로고    scopus 로고
    • Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone
    • Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62:33-43.
    • (2010) Arthritis Rheum , vol.62 , pp. 33-43
    • Garnero, P.1    Thompson, E.2    Woodworth, T.3    Smolen, J.S.4
  • 30
    • 84924967862 scopus 로고    scopus 로고
    • Serum levels of osteoprotegerin and RANKL in patients with rheumatoid arthritis and their relation to bone mineral density and disease activity
    • Fadda S, Hamdy A, Albulkhair E, Elsify HM, Mostafa A. Serum levels of osteoprotegerin and RANKL in patients with rheumatoid arthritis and their relation to bone mineral density and disease activity. Egypt Rheumatologist. 2015;37:1-6.
    • (2015) Egypt Rheumatologist , vol.37 , pp. 1-6
    • Fadda, S.1    Hamdy, A.2    Albulkhair, E.3    Elsify, H.M.4    Mostafa, A.5
  • 31
    • 36249012519 scopus 로고    scopus 로고
    • Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis-relationship with bone mineral density, disease activity and bone turnover
    • Oelzner P, Franke S, Lehmann G, Eidner T, Müller A, Wolf G, et al. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis-relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol. 2007;26:2127-35.
    • (2007) Clin Rheumatol , vol.26 , pp. 2127-2135
    • Oelzner, P.1    Franke, S.2    Lehmann, G.3    Eidner, T.4    Müller, A.5    Wolf, G.6
  • 32
    • 84930521037 scopus 로고    scopus 로고
    • Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
    • Torring O. Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2015;7:88-102.
    • (2015) Ther Adv Musculoskelet Dis , vol.7 , pp. 88-102
    • Torring, O.1
  • 33
    • 36749086534 scopus 로고    scopus 로고
    • Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists
    • González-Alvaro I, Ortiz AM, Tomero EG, Balsa A, Orte J, Laffon A, et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:1675-8.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1675-1678
    • González-Alvaro, I.1    Ortiz, A.M.2    Tomero, E.G.3    Balsa, A.4    Orte, J.5    Laffon, A.6
  • 34
    • 0031005576 scopus 로고    scopus 로고
    • Osteoprotegerin: a novel secreted protein involved in the regulation of bone density
    • Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-19.
    • (1997) Cell , vol.89 , pp. 309-319
    • Simonet, W.S.1    Lacey, D.L.2    Dunstan, C.R.3    Kelley, M.4    Chang, M.S.5    Lüthy, R.6
  • 35
    • 84866405043 scopus 로고    scopus 로고
    • Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis
    • Kanbe K, Nakamura A, Inoue Y, Hobo K. Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis. Rheumatol Int. 2012;32:2669-74.
    • (2012) Rheumatol Int , vol.32 , pp. 2669-2674
    • Kanbe, K.1    Nakamura, A.2    Inoue, Y.3    Hobo, K.4
  • 36
    • 77956050875 scopus 로고    scopus 로고
    • Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis
    • van Tuyl LH, Voskuyl AE, Boers M, Geusens P, Landewé RB, Dijkmans BA, et al. Baseline RANKL:OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis. 2010;69:1623-8.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1623-1628
    • van Tuyl, L.H.1    Voskuyl, A.E.2    Boers, M.3    Geusens, P.4    Landewé, R.B.5    Dijkmans, B.A.6
  • 38
  • 40
    • 82155192252 scopus 로고    scopus 로고
    • Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities
    • Karsdal MA, Woodworth T, Henriksen K, Maksymowych WP, Genant H, Vergnaud P, et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities. Arthritis Res Ther. 2011;13:215.
    • (2011) Arthritis Res Ther , vol.13 , pp. 215
    • Karsdal, M.A.1    Woodworth, T.2    Henriksen, K.3    Maksymowych, W.P.4    Genant, H.5    Vergnaud, P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.